and AD in the nationwide Danish registry. They identified 12 events of AD among 3432 HS patients. In adjusted analyses, there was no significant association noted (OR ¼ 1.44 [95% CI, 0.78-2.65]). Herein we have independently confirmed this result in a large US population-based sample, which will provide reassurances to HS patients and to the providers caring for them. Our analysis is limited because we could not isolate the HS cohort to the subset of familial patients with mutation of the -secretasecomponent of presenilin genes implicated in AD.
Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
To the Editor: Atopic dermatitis affects up to 25% of children and 2%-3% of adults worldwide. 1 Current systemic therapies for chronic, severe, and recalcitrant disease exist, including phototherapy, systemic corticosteroids, cyclosporine, methotrexate, azathioprine, and mycophenolate. 2 Although they are effective, close laboratory monitoring and inconvenience have limited their widespread use. Apremilast is an oral phosphodiesterase-4 (PDE-4) inhibitor proven effective for psoriasis vulgaris and psoriatic arthritis, but its use in atopic dermatitis has rarely been reported. 3 We present here the successful use of apremilast for 4 patients with chronic, severe atopic dermatitis, and a fifth patient with severe acral eczematous dermatitis.
Five patients were included; 3 patients fit the diagnostic criteria for atopic dermatitis. The other 2 patients had confirmatory skin biopsies showing spongiotic dermatitis. Patient characteristics are detailed in Table I . Severe pruritus was a common feature associated with their skin manifestations. Before starting apremilast, patients received extensive treatment that included oral prednisone, methotrexate, narrowband ultraviolet B, azathioprine, topical corticosteroids, calcineurin inhibitors, hydroxyzine, and coal tar with unsatisfactory results (Table I) .
All of our patients expressed concerns about the short-term and long-term adverse effects of systemic anti-inflammatory therapies. The decision was made to begin treatment with apremilast 30 mg twice daily using the standard titration as provided in the package insert. Within 2-4 weeks of initiating apremilast, all of the patients reported noticeable improvement in erythema, scaling, and xerosis of skin lesions (Fig 1) . All patients noted significant improvement of associated pruritus. Using the physician's global assessment, 2 patients were judged to achieve [75% improvement of their atopic dermatitis (Table I) . Patient 5, who had Table I . We present here the successful use of apremilast to treat 4 patients with chronic, severe, recalcitrant atopic dermatitis and 1 patient with hand and foot dermatitis. Limitations to this study include a limited number of patients, the lack of objective measurements of disease severity (such as the Scoring Atopic Dermatitis or the Eczema Area and Severity Index), and the lack of quality of life measurements, specifically regarding pruritus. Apremilast, a PDE-4 inhibitor, works by increasing intracellular adenosine monophosphate, which activates protein kinase A and other intermediate mediators, resulting in inhibition of proinflammatory cytokine production and decreased inflammation. 4 Although high cost of therapy can be a barrier, its use has many benefits, such as rapid onset of action, few contraindications, and no need for laboratory monitoring or long-term adverse effects compared with biologic and other immunosuppressive agents. The mechanism whereby apremilast reduces pruritus independent of reduction in cutaneous inflammation is incompletely understood and deserves further investigation. In addition, the drastic improvement of patient 5's recalcitrant hand and foot dermatitis indicates an important therapeutic potential of apremilast for this subtype of atopic dermatitis. Ethnicity affects the presenting severity of psoriasis
To the Editor: Psoriasis is a chronic inflammatory condition that occurs worldwide; however, data on the clinical features of psoriasis in racial minorities are scarce. 1 Recent population-based studies in the United States have observed a prevalence of 3.6% in whites, 1.9% in African Americans, and 1.6% in Hispanics. 2 However, there have been few studies specifically looking at the severity of psoriasis in different ethnicities. Some studies have been published on the clinical variation of psoriasis in skin of color, specifically African Americans who may present with a different set of defining characteristics. 3 These patients may present with less conspicuous erythema that may appear violaceous or hyperpigmented, making it harder to appreciate areas of active inflammation compared to lighter skin. 4 In addition, Asians have been reported to have greater body surface area involvement at initial presentation compared to whites.
5
The purpose of this cross-sectional study was to determine whether there are any differences in the presenting severity of psoriasis based on ethnicity. We examined a database of psoriasis patients seen at the University of California, San Francisco Department of Dermatology (Table I ). The database included 848 patients with psoriasis between 2006 and 2016, with 62% self-identified as white, 26% Asian, 8% Hispanic, 2% African American, and 2% 
